Venn Life Sciences Holdings PLC (LON:VENN) has forecast better-than-expected annual results after winning bigger contracts this year.
Tony Richardson, chief executive, tells Proactive Investors the company has “moved from the realm of a typical contract size being €300,000/€400,000/€500,000 per piece,” to “a pipeline that has a lot more multi million euro pieces of business in it.”
He says the company is seeing a “healthy mix” of both recurring revenue from existing clients as well as a “nice pattern” of referrals or recommendations from existing customers to new potential clients.